Literature DB >> 16014768

Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans.

Maki Shimizu1, Kaori Fuse, Kazuho Okudaira, Ryuichiro Nishigaki, Kazuya Maeda, Hiroyuki Kusuhara, Yuichi Sugiyama.   

Abstract

Fexofenadine hydrochloride (FEX), a second generation H(1)-receptor antagonist, is mainly eliminated from the liver into bile in unchanged form. Recent studies have shown that FEX can be accepted by human MDR1 (P-glycoprotein), OATP1A2 [organic anion-transporting polypeptide (OATP)-A, and OATP2B1 (OATP-B)] expression systems. However, other transporters responsible for the hepatic uptake of FEX have not yet been identified. In the present study, we evaluated the contribution of OATP family transporters, namely OATP1B1 (OATP2/OATP-C), OATP1B3 (OATP8), and OATP2B1 (OATP-B), to FEX uptake using transporter-expressing HEK293 (human embryonic kidney) cells. The uptake of FEX in OATP1B3-expressing cells was significantly greater than that in vector-transfected cells. On the other hand, OATP1B1- or OATP2B1-mediated uptake of FEX was not statistically significant. OATP1B3-mediated transport could be explained by a one-saturable component with a Michaelis constant (K(m)) of 108 +/- 11 microM. The inhibitory effect of FEX on the uptake of estrone-3-sulfate (E(1)S), cholecystokinin octapeptide (CCK-8), and 17beta-estradiol-17beta-d-glucuronide (E(2)17betaG) was also examined. Both OATP1B1- and OATP1B3-mediated E(2)17betaG uptake was inhibited by FEX. The K(i) values were 148 +/- 61 and 205 +/- 72 microM for OATP1B1 and OATP1B3, respectively. FEX also inhibited OATP1B3-mediated CCK-8 uptake and OATP1B1-mediated E(1)S uptake with a K(i) value of 83.3 +/- 15.3 and 257 +/- 84 microM, respectively, suggesting that FEX could not be used as a specific inhibitor for OATP1B1 and OATP1B3, although FEX was preferentially accepted by OATP1B3. In conclusion, this is, to our knowledge, the first demonstration that OATP1B3 is thought to be a major transporter involved in hepatic uptake of FEX in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014768     DOI: 10.1124/dmd.105.004622

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Interactions of green tea catechins with organic anion-transporting polypeptides.

Authors:  Megan Roth; Barbara N Timmermann; Bruno Hagenbuch
Journal:  Drug Metab Dispos       Date:  2011-01-28       Impact factor: 3.922

Review 2.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.

Authors:  Hiroyuki Kusuhara; Hidetoshi Furuie; Akihiro Inano; Akihiro Sunagawa; Saiko Yamada; Chunyong Wu; Shinya Fukizawa; Nozomi Morimoto; Ichiro Ieiri; Mariko Morishita; Kiminobu Sumita; Hiroshi Mayahara; Takuya Fujita; Kazuya Maeda; Yuichi Sugiyama
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

4.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

Authors:  Evita van de Steeg; Els Wagenaar; Cornelia M M van der Kruijssen; Johanna E C Burggraaff; Dirk R de Waart; Ronald P J Oude Elferink; Kathryn E Kenworthy; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 5.  Fruit juice inhibition of uptake transport: a new type of food-drug interaction.

Authors:  David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

6.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

7.  Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Authors:  Mikiko Shimizu; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

Review 8.  Pharmacogenomics of human OATP transporters.

Authors:  Jörg König; Annick Seithel; Ulrike Gradhand; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-09       Impact factor: 3.000

9.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Authors:  E D Kharasch; P S Bedynek; A Walker; D Whittington; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

10.  PharmGKB very important pharmacogene: SLCO1B1.

Authors:  Connie Oshiro; Lara Mangravite; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.